Achillion Pharmaceuticals is an innovative biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. The company’s discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is currently developing treatments for HIV infection, chronic hepatitis C infection and serious hospital-based bacterial infections. The company’s focus is currently on developing three clinical candidates for the treatment of chronic hepatitis C infection. First, Achillion is developing ACH-1625, a proprietary NS3 protease inhibitor currently in early-stage clinical development. Second, Achillion is developing ACH-1095, a candidate from a unique class of compounds called NS4A antagonists that have been demonstrated to be synergistic or additive with other inhibitors under development for HCV infection. Finally, Achillion is developing ACH-2684, a highly potent, pan-genotypic inhibitor of HCV NS3 protease with pico-molar potency. Achillion is also developing ACH-702, its candidate for the treatment of serious, resistant bacterial infections. Each of these programs was discovered through Achillion’s own proprietary internal drug discovery efforts.
PneumRx develops minimally invasive medical devices, seeking to meet the market need for better, minimally invasive treatments for emphysema patients. The company’s innovative implantable device, the RePneu® Lung Volume Reduction Coil (LVRC™), is an investigational device designed to improve lung function in patients with emphysema by reducing lung volume using minimally invasive means. Improvement in lung function is often felt within hours after the procedure and patients generally continue to improve in pulmonary function, physical endurance and activities of daily living over several months post procedure. The RePneu LVRC, not yet available commercially, is currently undergoing human clinical trials that have shown the RePneu LVRC device and procedure to be well-tolerated, with no unanticipated adverse events experienced by any of the clinical trial patients.
Prolong Pharmaceuticals is a biopharmaceutical company whose core technology is an FDA-approved delivery system for protein-based biopharmaceuticals, known as PEGylation. This process involves the chemical attachment of polyethylene glycol (“PEG”) to a therapeutic protein. The result is a product that has significantly improved therapeutic properties, affords better patient compliance and reduced side effects. Prolong seeks to develop long-acting biopharmaceuticals through its own research and by collaboration to be sold by the company or licensed to third parties in other geographic areas.
CardioFocus develops, manufactures and markets proprietary, disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias such as atrial fibrillation. The CardioFocus catheter promises rapid, effective and permanent isolation of the pulmonary veins while overcoming the difficulties inherent in the current RF ablation procedures. Guided via integrated endoscopic visualization, the catheter helps physicians to accomplish ablation by projecting a series of overlapping arcs of both visible and infrared laser light upon the atrial wall surrounding each vein. Complete isolation is generally obtained with several 60-second energy deliveries — promising a great advantage in speed and precision in comparison to the large number of ablations required in current RF ablation procedures.
KBL Healthcare Ventures is a team of investment professionals with prior experiences as senior executives, clinical practitioners and venture capitalists. The company has funded and invested in dozens of highly successful healthcare industry companies, bringing managerial and technical expertise to emerging companies, while also identifying a path to bring new medical technologies to the public.
Sychordia, a new center for Transcranial Magnetic Stimulation (TMS), is the first FDA-approved treatment for depression that has been proven effective even for those who have not benefited from medicine or therapy. The first Sychordia center is located at 50 East 72nd Street in Manhattan. TMS applies low-dose magnetic pulses about the strength of an MRI to the parts of the brain associated with depression. In the FDA trials, more than 10,000 active TMS treatments were performed on depressed patients. The trials showed that approximately one in two patients treated experienced significant improvement in their symptoms of depression, and approximately one in three patients experienced complete relief from their depression at the end of six weeks of treatment. The treatment is safe and has none of the side effects associated with most anti-depressant medications — there is no weight gain, sexual dysfunction, sedation or memory impairment.
Summer Infant, Inc. is a designer, marketer and distributor of premium juvenile products for parents and caregivers under the Summer Infant and Kiddopotamus brand names. Founded in 1984 with the invention of the baby bouncing seat, the company is based on the philosophy that innovation is a key attribute in driving new product development. Summer Infant annually delivers new and existing products in categories such as bouncers, gates, bathing, safety, monitors, infant health, bedrails, boosters, potty seats, soft goods, bedding, large furniture, nursery and travel accessories, organic products, and more that exceed consumer’s standards.
Summit Technology is a leading developer, manufacturer and marketer of ophthalmic laser systems designed to correct common vision disorders such as nearsightedness, farsightedness and astigmatism. In 1995, Summit was the first excimer laser company to receive FDA approval for its Apex excimer laser system for the correction of mild to moderate myopia in the United States. In addition, through its wholly owned subsidiary, Lens Express, Summit sells contact lenses and related products.
Candela Corporation manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. The company offers the most comprehensive and technologically sophisticated aesthetic devices in the industry. Founded in 1970, the company markets and services its products in 86 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 20 years ago, and currently has an installed base of more than 14,000 systems worldwide.
Neuronetics Inc. is a medical device company that has developed an effective, non-invasive device to treat depression. The technology is FDA approved and is called TMS (transcranial magnetic stimulation), and the treatment has been proven effective in a multitude of studies. The company has reported that it has hired Christopher Thatcher as its new President & CEO, December 2014.